Dynavax Technologies Azioni (NASDAQ: DVAX)

Ultime notizie per Dynavax Technologies (NASDAQ:DVAX) Azioni

Dynavax Technologies

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies Corp

<p>Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) will release its quarterly earnings report on Thursday, 2024-11-07. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Dynavax Technologies to report an <strong>earnings per share</strong> (EPS) of $0.11.</p>
<p>The announcement from Dynavax Technologies is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company beat EPS by $0.02, leading to a 6.97% increase in the share price the following trading session.</p>
<p>Here's a look at Dynavax Technologies's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.06</td>
<td>-0.02</td>
<td>-0.01</td>
<td>-0.01</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.08</td>
<td>-0.07</td>
<td>0</td>
<td>0.10</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>7.000000000000001%</td>
<td>-5.0%</td>
<td>2.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730919682_0.png" alt="eps graph" /></p>
<h3>Performance of Dynavax Technologies Shares</h3>
<p>Shares of Dynavax Technologies were trading at $12.01 as of November 05. Over the last 52-week period, shares are down 6.38%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Insights on Dynavax Technologies</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Dynavax Technologies.</p>
<p>The consensus rating for Dynavax Technologies is Buy, based on 2 analyst ratings. With an average one-year price target of $22.0, there's a potential 83.18% upside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of Myriad Genetics and Kiniksa Pharmaceuticals, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>The consensus among analysts is an Neutral trajectory for Myriad Genetics, with an average 1-year price target of $32.75, indicating a potential 172.69% upside.</li>
<li>The consensus outlook from analysts is an Outperform trajectory for Kiniksa Pharmaceuticals, with an average 1-year price target of $38.33, indicating a potential 219.15% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for Myriad Genetics and Kiniksa Pharmaceuticals, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dynavax Technologies</td>
<td>Buy</td>
<td>22.48%</td>
<td>$61.81M</td>
<td>1.81%</td>
</tr>
<tr>
<td>Myriad Genetics</td>
<td>Neutral</td>
<td>15.26%</td>
<td>$147.10M</td>
<td>-4.89%</td>
</tr>
<tr>
<td>Kiniksa Pharmaceuticals</td>
<td>Outperform</td>
<td>67.37%</td>
<td>$62.80M</td>
<td>-2.91%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Dynavax Technologies ranks highest in Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, Dynavax Technologies is at the bottom compared to its peers.</p>
<h3>Delving into Dynavax Technologies's Background</h3>
<p>Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.</p>
<h3>Breaking Down Dynavax Technologies's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Dynavax Technologies showcased positive performance, achieving a revenue growth rate of <strong>22.48%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Dynavax Technologies's net margin is impressive, surpassing industry averages. With a net margin of <strong>15.43%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Dynavax Technologies's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>1.81%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Dynavax Technologies's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.14%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>0.39</strong>, Dynavax Technologies faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<p><a href="https://www.benzinga.com/quote/DVAX/earnings"><strong>To track all earnings releases for Dynavax Technologies visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

DVAX

Insights into Dynavax Technologies's Upcoming Earnings

<p>Dynavax Technologies Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>), a commercial-stage biopharmaceutical company developing and&nbsp;commercializing innovative vaccines, today announced that its Board of Directors has adopted a limited-duration stockholder rights plan, effective immediately (the "Rights Plan").</p>
<p>The Dynavax Board adopted the Rights Plan in response to the recent rapid accumulations of stock by Deep Track Capital, which recently disclosed in a Schedule 13D/A filing its ownership of 13.6% of the Company's outstanding common stock. The Rights Plan is intended to protect the investment of Dynavax stockholders during a period in which it believes shares of the Company do not reflect the inherent value of the business or its long-term growth potential. The Rights Plan should reduce the likelihood that any person or group gains control of Dynavax through open market accumulation without paying all stockholders an appropriate control premium or without providing the Board sufficient time to make informed judgments and take actions that are in the best interests of all stockholders.</p>
<p>The Rights Plan, which is similar to other plans adopted by publicly held companies, does not contain any dead-hand, slow-hand, no-hand or similar feature that limits the ability of a future Board to redeem the rights. The Rights Plan does not limit the Board's ability to engage in discussions or pursue transactions it believes are in the best interests of all stockholders.</p>


News

Management

Dynavax Adopts Limited-Duration Stockholder Rights Plan, Effective Immediately

<p>HC Wainwright &amp; Co.  analyst Edward White   reiterates Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) with a Buy and maintains $29 price target.</p>


Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Dynavax Technologies, Maintains $29 Price Target

<p>Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $25.5, a high estimate of $29.00, and a low estimate of $15.00. This current average represents a 4.67% decrease from the previous average price target of $26.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1723132810_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Dynavax Technologies by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul Choi</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Dynavax Technologies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Dynavax Technologies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Dynavax Technologies's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Dynavax Technologies's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DVAX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Dynavax Technologies analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Dynavax Technologies</h2>
<p>Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.</p>
<h3>Dynavax Technologies: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Dynavax Technologies's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>22.48%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Dynavax Technologies's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>15.43%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Dynavax Technologies's ROE excels beyond industry benchmarks, reaching <strong>1.81%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Dynavax Technologies's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.14%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Dynavax Technologies's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.39</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Assessing Dynavax Technologies: Insights From 4 Financial Analysts

<p>Goldman Sachs  analyst Paul Choi   maintains Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) with a Neutral and lowers the price target from $20 to $15.</p>


Goldman Sachs Maintains Neutral on Dynavax Technologies, Lowers Price Target to $15

Guidance

Dynavax Reaffirms 2024 HEPLISAV-B Net Product Revenue Guidance Of $265M-$280M

<p>Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.06 by 33.33 percent. This is a 166.67 percent increase over earnings of $0.03 per share from the same period last year.  The company reported quarterly sales of $73.795 million which missed the analyst consensus estimate of $76.102 million by 3.03 percent.  This is a 22.48 percent increase over sales of $60.249 million the same period last year.</p>


Earnings Beats

Earnings Misses

Dynavax Technologies Q2 2024 GAAP EPS $0.08 Beats $0.06 Estimate, Sales $73.795M Miss $76.102M Estimate

Dynavax Reappoints Kelly MacDonald As CFO Effective August 1, 2024; Ryan Spencer Continues As CEO After Serving As Interim CFO During MacDonald's Maternity Leave; No Change In MacDonald's Compensation

Biotech

General

Dynavax Initiates Phase 1/2 Study Of Novel Shingles Vaccine Program Evaluating Safety, Tolerability And Immunogenicity Of Z-1018

<p>Tuesday,&nbsp;<strong>Dynavax Technologies Corporation</strong>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>)&nbsp;provided a regulatory update for its supplemental Biologics License Application (sBLA) to include a four-dose HEPLISAV-B vaccine regimen for adults on hemodialysis.&nbsp;</p>
<p>The FDA has issued a Complete Response Letter stating that the application did not provide sufficient data to fully evaluate the effectiveness or safety of a four-dose regimen of HEPLISAV-B.&nbsp;</p>
<p>The CRL has no impact on the approved indication for HEPLISAV-B in the U.S., the European Union, and&nbsp;Great Britain, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18&nbsp;years of age&nbsp;and older.&nbsp;</p>
<p>The CRL also does not affect the approval decision&nbsp;received from&nbsp;the European Commission in&nbsp;October 2023&nbsp;for the four-dose HEPLISAV-B&nbsp;regimen for the adult hemodialysis population.</p>
<p>The supplemental application included clinical immunogenicity and safety data from the Phase 1 HBV-24 study of a four-dose regimen of HEPLISAV-B in 119 adults undergoing hemodialysis, as well as five supportive clinical trials of HEPLISAV-B in adults with chronic kidney disease or undergoing hemodialysis.&nbsp;</p>
<p>The CRL stated that the data from HBV-24&nbsp;were insufficient&nbsp;due to the destruction of data source documents by a third-party clinical trial site operator for approximately half of the subjects enrolled in the trial.&nbsp;</p>
<p>In addition, the total number of subjects in the single-arm HBV-24 study&nbsp;was&nbsp;deemed&nbsp;insufficient&nbsp;to evaluate the four-dose regimen&#8217;s safety.</p>
<p>&#8220;We are reviewing the agency&#8217;s feedback and intend to request a meeting with the FDA to evaluate options for providing additional data to support the four-dose regimen for this vulnerable patient population in the U.S.,&#8221; said&nbsp;Rob Janssen,&nbsp;Dynavax&#8217;s Chief Medical Officer.</p>
<p>In&nbsp;first quarter&nbsp;2024,&nbsp;HEPLISAV-B vaccine&nbsp;achieved net product revenue of&nbsp;$47.8 million&nbsp;up from&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/n38711968/dynavax-reports-first-quarter-2024-financial-results-and-provides-business-updates" rel="noreferrer noopener">$43.5 million&nbsp;a year ago</a>.</p>
<p>HEPLISAV-B&nbsp;total estimated market share in the U.S. increased to approximately 41%, compared to approximately 37% at the end of the first quarter&nbsp;2023.</p>
<p><strong>Price Action:</strong>&nbsp;At last check on Tuesday, DVAX shares were down 1.36% at $10.88.</p>


Health Care

Movers

Trading Ideas

FDA Declines To Approve Expanded Use of Dynavax's Hepatitis B Vaccine In Hemodialysis Patients

FDA Issued Complete Response Letter To Dynavax Saying sBLA For Four-Dose HEPLISAV-B Regimen Did Not Provide Sufficient Data To Support Full Evaluation Of Effectiveness Or Safety

WIIM

Dynavax shares are trading lower after the company reported worse-than-expected Q1 financial results.

<ul>
<li>HEPLISAV-B net product revenue between approximately&nbsp;$265&nbsp;-&nbsp;$280 million, including approximately&nbsp;$3 million&nbsp;in ex-U.S. sales through commercialization partnership in Germany&nbsp;</li>
<li>HEPLISAV-B gross margin of approximately&nbsp;80%</li>
</ul>


Dynavax Reaffirms Full Year 2024 Financial Guidance; Expects Cash & Equivalents To Be Higher Y/Y At December 31, 2024

<p>Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.03) by 133.33 percent.  The company reported quarterly sales of $50.790 million which missed the analyst consensus estimate of $54.975 million by 7.61 percent.  This is a 8.24 percent increase over sales of $46.925 million the same period last year.</p>


Dynavax Technologies Q1 2024 GAAP EPS $(0.07) Misses $(0.03) Estimate, Sales $50.790M Miss $54.975M Estimate

Dynavax Technologies Sees FY24 Net Product Revenue $265M-$280M Vs $290.628M Est.

<p><strong>Dynavax Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) reported its Q4 earnings results on Thursday, February 22, 2024 at 04:05 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Dynavax Technologies missed estimated earnings by 100.0%, reporting an EPS of $0.0 versus an estimate of $-0.01.</p>
<p>Revenue was down $128.90 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat on EPS by $0.11 which was followed by a 1.07% increase in the share price the next day.</p>
<p>Here's a look at Dynavax Technologies's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2023</strong></th>
<th><strong>Q2 2023</strong></th>
<th><strong>Q1 2023</strong></th>
<th><strong>Q4 2022</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.01</td>
<td>-0.09</td>
<td>-0.13</td>
<td>0.43</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.10</td>
<td>0.03</td>
<td>-0.19</td>
<td>0.45</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>60.30M</td>
<td>48.38M</td>
<td>38.59M</td>
<td>179.60M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>69.51M</td>
<td>60.25M</td>
<td>46.92M</td>
<td>184.49M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Dynavax Technologies <a href="https://www.benzinga.com/quote/DVAX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Dynavax Technologies: Q4 Earnings Insights

3 'Repeatable' Biotech Trades

Morgan Stanley identifies 39 stocks likely to face tax loss selling pressure

Morgan Stanley's list of tax loss selling stocks

Dynavax (DVAX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Edward White from H.C. Wainw...

Dynavax's Market Expansion and Financial Upside Prompt 'Buy' Rating

Analyst Roy Buchanan from JMP Securities reiterated a Buy rating on Dynavax (DVAX – Research Report) and keeping the price target at $29.00. Roy Bu...

Optimistic Buy Rating for Dynavax Driven by Strong Vaccine Pipeline and Competitive Advantage

Dynavax's (DVAX) board has adopted a limited-duration stockholder rights plan, effective immediately. The board adopted the Rights Plan in response...

Dynavax adopts limited-duration stockholder rights plan

Dynavax Technologies adopts limited-duration stockholder rights plan

Dynavax ( ($DVAX) ) has provided an announcement. Dynavax Technologies has implemented a stockholder rights plan to safeguard its shareholders' int...

Dynavax Implements Stockholder Rights Plan

3 Market Predictions For November

Dynavax Q3 2024 Earnings Preview

ACTV

ADBE

AFMC

AFSM

APTV

ARCH

ARKK

AVUV

BAPR

BIIB

CHRD

CIVI

FOLD

IIIN

IRDM

IVOO

IVOV

MAGS

NBIX

NTLA

NVEE

PLAB

PRGO

PRVA

PTEN

RGEN

ROCK

SMPL

SPLV

SPMD

SPMO

SPMV

SPSM

SPTM

SPUS

SPUU

SPVM

SPVU

SPXE

SPXL

SPXN

SPXS

SPXT

SPXU

SPXV

SPYD

SPYG

SPYV

SPYX

SQEW

SQLV

SSPY

SVAL

SYLD

TALO

TMDV

TPHD

TPLC

TPSC

UAUG

UJAN

UMAR

UMAY

UOCT

UPRO

USMC

USMF

USPH

USVM

XLRE

XPEL

Press Releases

Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates

Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S.

Dynavax to Present at Upcoming Investor Conferences

Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program

Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024

Dynavax Reports Second Quarter 2024 Financial Results and Provides Business Updates

Lantheus Appoints Julie Eastland as New Board Member

Dynavax to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024

Dynavax Adopts Limited-Duration Stockholder Rights Plan

Glancy Prongay & Murray LLP Announces Investigation of Dynavax Technologies Corporation (DVAX)

Comments

Dynavax Technologies

Notizie

Ultime notizie per Dynavax Technologies (NASDAQ:DVAX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO